Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Netupitant-Palonosetron FDC Market Poised To Hit $608.99 Billion By 2030 With A 9.6% CAGR
The netupitant-palonosetron fdc market size has experienced significant growth over recent years. This market is anticipated to expand from $384.5 billion in 2025 to $422.35 billion in 2026, progressing at a compound annual growth rate (CAGR) of 9.8%. Historically, this expansion was driven by several factors, including the restricted availability of netupitant and palonosetron formulations, the dependence on traditional antiemetic treatments, an expanding population of chemotherapy patients, the rising number of hospital and oncology clinic establishments, and enhanced awareness concerning CINV management.
The netupitant-palonosetron fdc market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $608.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This projected growth during the forecast period is attributable to several factors, including the creation of new fdc formulations, the broadened use of oral and sublingual drug delivery methods, increasing financial commitments to oncology therapies, the implementation of individualized antiemetic protocols, and enhanced market access via online and specialized pharmacies. Key trends for the forecast period encompass a greater acceptance of fixed-dose combination (fdc) therapies, a surge in the application of oral and sublingual treatments for nausea, the expansion of chemotherapy and oncology care infrastructure, heightened awareness concerning the management of postoperative nausea and vomiting, and an elevated emphasis on patient-focused drug delivery systems.
Get A Free Sample Report With In-Depth Market Insights:
Netupitant-Palonosetron FDC Market Growth Momentum: What Factors Are Shaping Demand?
The expanding occurrence of cancer is anticipated to drive the growth of the netupitant-palonosetron fixed-dose combination (FDC) market moving forward. Cancer is defined as a collection of diseases characterized by the uncontrolled proliferation and spread of abnormal cells within the body. The escalating prevalence of cancer is attributed to lifestyle choices such as an inadequate diet, smoking, physical inactivity, and excessive alcohol intake. The netupitant-palonosetron fixed-dose combination (FDC) enhances cancer treatment by bringing together two effective antiemetic agents, thereby preventing both immediate and delayed chemotherapy-induced nausea and vomiting. These combinations improve patient comfort and adherence to treatment, fostering better overall care outcomes. For instance, according to Cancer Australia, an Australia-based government agency, in February 2025, there were 4,641 new pancreatic cancer cases in 2024, with 2,414 in males and 2,227 in females, marking an increase from 3,968 cases in 2023. Consequently, the rising prevalence of cancer is a significant factor driving the expansion of the netupitant-palonosetron fixed-dose combination (FDC) market.
Netupitant-Palonosetron FDC Market Segment Analysis Spotlighting Growth Areas
The netupitant-palonosetron fdc market covered in this report is segmented –
1) By Product Type: Netupitant, Palonosetron, Fixed Dose Combination (FDC)
2) By Route Of Administration: Oral Administration, Intravenous (IV) Administration
3) By Application: Chemotherapy Induced Nausea And Vomiting (CINV), Postoperative Nausea And Vomiting (PONV)
4) By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies, Specialty Clinics
Subsegments:
1) By Netupitant: Oral Netupitant, Injectable Netupitant
2) By Palonosetron: Oral Palonosetron, Injectable Palonosetron
3) By Fixed Dose Combination: Oral Fixed Dose Combination, Intravenous Fixed Dose Combination
Netupitant-Palonosetron FDC Market Trends Redefining Industry Growth
Leading companies in the netupitant-palonosetron fixed dose combination (FDC) market are concentrating on developing sophisticated formulation products, such as ready-to-use intravenous formulations, to enhance both patient convenience and treatment effectiveness. These ready-to-use intravenous formulations are pre-prepared, sterile drug solutions that eliminate the requirement for dilution or mixing, aiding netupitant-palonosetron fixed dose combination (FDC) products by simplifying their administration and reducing potential preparation errors. For instance, in June 2024, Helsinn Group, a Switzerland-based pharmaceutical company, introduced AKYNZEO (fosnetupitant/palonosetron) injection, a ready-to-use vial made available in the United States. This new formulation is designed to streamline preparation and administration for healthcare providers, thereby boosting convenience in clinical settings. The injection requires no reconstitution or dilution and can be infused directly from the vial using an integrated hanging strap.
Netupitant-Palonosetron FDC Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the netupitant-palonosetron fdc market are Taiho Pharmaceutical Co. Ltd., Aurobindo Pharma Limited, Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd, Dr. Reddy’s Laboratories Ltd., Zhejiang Tiantai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Helsinn Group, Heron Therapeutics Inc., Metrochem API Private Limited, Mundipharma Pty Ltd, Guangzhou Tosun Pharmaceutical Co. Ltd., Tesaro Inc., Accord Healthcare Ltd., Century Pharmaceuticals Ltd., Specialised Therapeutics Australia Pty Ltd., Aark Pharmaceuticals Ltd., Chemicea Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd.
View The Full Netupitant-Palonosetron FDC Market Report:
Netupitant-Palonosetron FDC Market Geographic Distribution And Regional Opportunities
North America was the largest region in the netupitant-palonosetron fixed dose combination (FDC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the netupitant-palonosetron fdc market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
